REG - Oxford Biomedica PLC - FUNDRAISING OF £10 MILLION <Origin Href="QuoteRef">OXB.L</Origin> - Part 2

Oxford BioMedicaAnnouncement

13/09/2016 07:06

- Part 2: For the preceding part double click  ID:nRSM6532Ja 

accordingly
disclaims all and any liability, whether arising in tort, contract or
otherwise, which it might otherwise be found to have in respect of this
Announcement or any such statement. 
 
Roth Capital, which is authorised in the US by the Financial Industry
Regulatory Authority (''FINRA''), is acting exclusively for the Company as US
Placement Agent and no-one else in relation to the Fundraising and Admission,
will not regard any other person (whether or not a recipient of the
Announcement) as a client in relation to the Fundraising or Admission and will
not be responsible to anyone other than the Company for providing the
protections afforded to clients of Roth Capital nor for providing advice in
relation to the Fundraising or any other transaction or arrangement referred
to in the Announcement and, apart from the responsibilities and liabilities,
if any, which may be imposed on Roth Capital by FINRA or any other US
regulatory authority, Roth Capital accepts no responsibility whatsoever and
makes no representation or warranty, express or implied, for or in respect of
the contents of the Announcement, including its accuracy, completeness or
verification, nor for any other statement made or purported to be made by, or
on behalf of, it, the Company, the Directors or any other person, in
connection with the Company, the Fundraising or Admission. Roth Capital and
its directors, officers, employees, advisors and affiliates each accordingly
disclaims all and any liability, whether arising in tort, contract or
otherwise, which it might otherwise be found to have in respect of the
Announcement or any such statement. 
 
This Announcement may contain forward-looking statements that reflect the
Group's current expectations regarding future events, including the clinical
development and regulatory clearance of the Group's product candidates, the
Group's ability to find partners for the development and commercialisation of
its product candidates, the business of the Company, and management plans and
objectives. The Company considers any statements that are not historical facts
as "forward-looking statements". Forward-looking statements involve risks and
uncertainties. Actual events could differ materially from those projected
herein and depend on a number of factors, including the success of the Group's
research strategies, the applicability of the discoveries made therein, the
successful and timely completion of pre-clinical and clinical studies with
respect to the Group's product candidates, the uncertainties related to the
regulatory process, the ability of the Group to identify and agree beneficial
terms with suitable partners for the commercialisation and/or development of
product candidates, as well as the achievement of expected synergies from such
transactions, the acceptance of product candidates by consumers and medical
professionals, the successful integration of completed mergers and
acquisitions and achievement of expected synergies from such transactions and
the ability of the Group to identify and consummate suitable strategic and
business combination transactions, the scaling-up of the Group's bioprocessing
activities and the risks described in the ''Risk Factors'' set out in the
Prospectus. 
 
When used in this Announcement the words "estimate", "project", "intend",
"aim", "anticipate", "believe", "expect", "should" and similar expressions, as
they relate to the Company or the management of the Group, are intended to
identify such forward-looking statements. Readers are cautioned not to place
undue reliance on these forward-looking statements which speak only as at the
date of this Announcement. Neither the Company nor any other member of the
Group undertakes any obligation publicly to update or revise any of the
forward-looking statements, whether as a result of new information, future
events or otherwise, save in respect of any requirement under applicable laws,
the Listing Rules, Prospectus Rules, Disclosure Rules and Transparency Rules
and other regulations. 
 
No statement in this Announcement or incorporation by reference into this
Announcement is intended as a profit forecast or profit estimate and no
statement in the Prospectus should be interpreted to mean that earnings or
earnings per Ordinary Share for the current or future financial years would
necessarily match or exceed the historical published earnings per Ordinary
Share. 
 
Save where expressly stated otherwise, neither the content of the Company's
website nor the content of any website accessible from hyperlinks on the
Company's website is incorporated into, or forms part of, this Announcement. 
 
This information is provided by RNS
The company news service from the London Stock Exchange